Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.

Next Previous
Trial Profile

Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilnidipine (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms CA-ATTEND
  • Sponsors Ajinomoto Pharma

Most Recent Events

  • 10 May 2011 Trial status has been changed from not yet recruiting to recruiting as reported University Hospital Medical Information Network - Japan.
  • 29 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top